We are leading the science in immunology through our research and development of advanced treatments for chronic, difficult to treat inflammatory diseases.
With two products on the market and a robust pipeline, our focus remains on bringing forward treatments for immunological diseases with significant unmet needs. In collaboration with Regeneron, we launched a first in class treatment for adults with moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease that can have severe physical and emotional effects on patients and their caregivers. Sanofi and Regeneron are currently conducting trials in atopic dermatitis in adolescents and the pediatric population as well as other immune-driven allergic and respiratory diseases including asthma, nasal polyps and eosinophilic esophagitis. Our second product targets adults with moderate-to-severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints. A trial is also underway looking at the potential of this same product to treat juvenile idiopathic arthritis.
Inspired by patients around the world
Above from left to right: Catherine, rheumatoid arthritis, USA; Hilde, atopic dermatitis, Norway; Vergard, atopic dermatitis, Norway